



**INFORMATION DISCLOSURE
CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.

4057-27

APPLICANT

GLENN et al.

FILING DATE

June 22, 1999

APPLN. NO.

09/337,746

GROUP

1644

RECEIVED
 MAR 07 2003
 TECH CENTER 1160012908

U.S. PATENT DOCUMENTS

*EXAMINE R INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AR	3,964,482	06/1976	Gerstel et al.			
BR	4,775,361	10/1988	Jacques et al.			
CR	5,003,987	04/1991	Grinwald			
DR	5,133,970	07/1992	Petereit et al.			
ER	5,182,109 C1	10/2001	Tamura et al.			
FR	5,250,023	10/1993	Lee et al.			
GR	5,279,544	01/1994	Gross et al.			
HR	5,688,523	11/1997	Garbe et al.			
IR	5,879,326	03/1999	Godshall et al.			
JR	5,993,849	11/1999	Assmus et al.			
KR	5,993,852	11/1999	Foldvari et al.			
LR	6,019,982	02/2000	Clements et al.			
MR	6,022,316	02/2000	Eppstein et al.			
NR	6,033,673	03/2000	Clements			
OR	6,033,684	03/2000	Norcia			
PR	6,063,399	05/2000	Assmus et al.			
QR	6,090,790	07/2000	Eriksson			
RR	6,142,939	11/2000	Eppstein et al.			
SR	6,149,919	11/2000	Domenighini et al.			
TR	6,165,458	12/2000	Foldvari et al.			
UR	6,165,500	12/2000	Cevc			
VR	6,190,367	02/2001	Hall			
WR	6,190,689	02/2001	Hoffmann et al.			
XR	6,207,184	03/2001	Ikeda et al.			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES
YR					
ZR					
AAR					
BBR					
CCR					

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

DDR	
EER	
FFR	
GGR	
HHR	
IIR	

*Examiner

E. J. H.

Date Considered

5/21/01



**INFORMATION DISCLOSURE
CITATION**

(attach several sheets if necessary)

ATTY. DOCKET NO.

4057-27

APPLICANT

GLENN et al.

FILING DATE

June 22, 1999

APPLN. NO.

09/337,746

GROUP

1644

TECH CENTER 1600/2900

MAR 07 2003

RECEIVED

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AR	6,256,533	07/2001	Yuzhakov et al.			
BR	6,290,991	09/2001	Roser et al.			
CR	6,312,612	11/2001	Sherman et al.			
DR	6,331,266	12/2001	Powell et al.			
ER	6,331,310	12/2001	Roser et al.			
FR	6,334,856	01/2002	Allen et al.			
GR	6,348,212	02/2002	Hymes et al.			
HR	6,348,450	02/2002	Tang et al.			
IR	6,365,178	04/2002	Venkateshwaran et al.			
JR	6,379,324	04/2002	Gartstein et al.			
KR	6,406,705	06/2002	Davis et al.			
LR	6,413,523	07/2002	Clements			
MR	6,440,096	08/2002	Lastovich et al.			
NR	6,451,240	09/2002	Sherman et al.			
OR	6,454,755	09/2002	Godshall			
PR	6,471,903	10/2002	Sherman et al.			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
QR	WO 95/17211	06/1995	WIPO		
RR	WO 96/06627	03/1996	WIPO		
SR	WO 96/19976	04/1996	WIPO		
TR	WO 97/04832	02/1997	WIPO		
UR	WO 97/07734	03/1997	WIPO		
VR	WO 98/00193	01/1998	WIPO		
WR	WO 98/29134	07/1998	WIPO		
XR	WO 99/13915	03/1999	WIPO		
YR	WO 99/26662	06/1999	WIPO		
ZR	WO 99/61078	12/1999	WIPO		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

AAR	
BBR	
CCR	
DDR	
EER	
FFR	
GGR	
HHR	
IIR	
JJR	
KKR	
LLR	

*Examiner

E. H. H.

Date Considered

5/2/03

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

APPLN. NO.

4057-27

09/337,746

APPLICANT

GLENN et al.

FILING DATE

GROUP

June 22, 1999

1644

U.S. PATENT DOCUMENTS

*EXAMINER

INITIAL

DOCUMENT NUMBER

DATE

NAME

CLASS

SUBCLASS

FILING DATE
IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

TRANSLATION

		DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
		AR	WO 99/47164	09/1999	WIPO			
		BR	WO 99/47165	09/1999	WIPO			
		CR	WO 99/47167	09/1999	WIPO			
		DR	WO 00/33812	06/2000	WIPO			
		FR	WO 00/74714	12/2000	WIPO			
		GR	WO 00/74763	12/2000	WIPO			
		HR	WO 00/74763 A3	12/2000	WIPO			
		IR	WO 00/74766	12/2000	WIPO			
		JR	WO 01/34185	05/2001	WIPO			
		KR	WO 01/90758	11/2001	WIPO			
		LR	WO 02/02179	01/2002	WIPO			
		MR	WO 02/05889	01/2002	WIPO			
		NR	WO 02/07813	01/2002	WIPO			
		OR	WO 02/64162	08/2002	WIPO			
		PR	WO 02/64193	08/2002	WIPO			
		QR	WO 02/74244	09/2002	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	RR	BECKER "Dengue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class I haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8 cytotoxic T cells (CTLs) - A novel approach to the protection of humans" Virus Genes 9 (1994) 33-45
	SR	BECKER "An analysis of the role of skin Langerhans cells (LC) in the cytoplasmic processing of HIV-1 peptides after "Peplotion" transepidermal transfer and HLA class I presentation to CD8 CTLs - An approach to immunization of humans" Virus Genes 9 (1994) 133-147
	UR	CASTLE "Clinical relevance of age-related immune dysfunction" Clin Infect Dis 31 (2000) 578-585
	VR	CHEN "Adjuvation of epidermal powder immunization" Vaccine 19 (2001) 2908-2917
	WR	CHEN "Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization" J Virol 75 (2001) 7956-7965
	XR	EL-GHORR "Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice" FEMS Immunol Med Micro 29 (2000) 255-261
	YR	GLUECK "Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine <i>Escherichia coli</i> heat-labile toxin as a mucosal adjuvant" J Infect Dis 181 (2000) 1129-1132
	ZR	GOCKEL "Transcutaneous immunization induces mucosal and systemic immunity: A potent method for targeting immunity to the female reproductive tract" Mol Immunol 37 (2000) 537-544

*Examiner

Date Considered


**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

APPLN. NO.

4057-27

09/337,746

APPLICANT

GLENN et al.

FILING DATE

GROUP

June 22, 1999

1644

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AR						
BR						
CR						
DR						

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
ER					
FR					

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

GR	HAGIWAR "Effectiveness and safety of mutant <i>Escherichia coli</i> heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine" Vaccine 19 (2001) 2071-2079
HR	HAGIWARA "Effects of intranasal administration of cholera toxin (or <i>Escherichia coli</i> heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain" Vaccine 19 (2001) 1652-1660
IR	HIOE "Comparison of adjuvant formulations of cytotoxic T cell induction using synthetic peptides" Vaccine 14 (1996) 412-418
JR	KATOH "Acute cutaneous barrier perturbation induces maturation of Langerhans' cells in hairless mice" Acta Derm Venereol (Stockh) 77 (1997) 365-369
KR	KUMAMOTO "Induction of tumor-specific protective immunity by <i>in situ</i> Langerhans cell vaccine" Nature Biotech 20 (2002) 64-69
LR	LIU "Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses" Vaccine 20 (2002) 42-48
MR	LU "Mutant <i>Escherichia coli</i> heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine" Vaccine 20 (2002) 1019-1029
NR	McCLUSKIE "Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates" Mol Med 5 (1999) 287-300
OR	OCKENHOUSE "Sequestrin, a CD36 recognition protein on <i>Plasmodium falciparum</i> malaria-infected erythrocytes identified by anti-idiotypic antibodies" Proc Natl Acad Sci USA 88 (1991) 3175-3179
PR	PODDA "The adjuvanted influenza vaccines with novel adjuvants: Experience with the MF59-adjuvanted vaccine" Vaccine 19 (2001) 2673-2680
QR	TAKIGAWA "Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis" Ann NY Acad Sci 941 (2001) 139-146
RR	"Tuberculin, Purified Protein Derivative, Tine Test" Physician's Desk Reference, 3 pages (2001)
SR	WATABE "Protection against influenza virus challenge by topical application of influenza DNA vaccine" Vaccine 19 (2001) 4434-4444
TR	
UR	
VR	
WR	
XR	

*Examiner

Date Considered